People with very high pre-treatment viral loads who took dolutegravir were significantly less likely to have experienced treatment failure nine months after starting treatment compared to people taking other drugs recommended for first-line treatment, a review of more than 2000 people in the United States shows.
The findings, published in the journal Open Forum Infectious Diseases, come from an analysis of a large US cohort, OPERA, which records data on around 90,000 people with HIV receiving treatment in 85 clinics across the United States.
Read the full story at Aidsmap.
Source : Aidsmap
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.